Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Manufacturer Audits Ramping Up In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

HRSA has launched only one audit of a drug manufacturer for compliance with 340B drug pricing requirements, and that is still ongoing, but the agency plans additional audits in 2015.


Related Content

Be ‘Audit-Ready’ When HRSA Calls For 340B Pricing Data, Attorneys Advise
340B Providers Should Report How They Use Drug Savings, House Members Say
GAO And Legislators Pushing HHS For Stronger 340B Oversight





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts